dismiss

Our Clean Sweep Live Auction is coming up fast! Next Tuesday, September 26th at 9:30AM EST

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

Forward Printable StoryPrint Comment

 

More HCB News

ASTRO Product Showcase Some of the products and services on display at ASTRO 2017

Montreal Heart Institute acquires da Vinci Xi for cardiac surgery in Canada Innovation for mitral valve and coronary artery bypass cardiac surgery

Penn Medicine treats first patient with Varian Halcyon radiation treatment platform Cuts down on time and costs

Third tricuspid valve stent implanted successfully in Italy Ministry of Health allowed the implant as a last resort for the patient

New study pinpoints most effective infection control practices Maintain a sterile operating field and track outcomes

Cardiologist salaries are on the rise in the U.S., survey finds Growing faster on the private side

International Atomic Energy Agency in partnership to get new Varian linac Will help the agency answer requests for standards and guidance

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Children undergoing CT scans for head injuries at risk for radiation overexposure Roughly half of kids visiting ER receive scans

Radiology Partners to acquire Southwest Diagnostic Imaging Joining with SDI 'represents about a 25 percent increase' in RP's size

UCLA Study Finds "Low-Risk" Prostate Cancer Often Not Low-Risk When Targeted Biopsy is Used

Press releases may be edited for formatting or style
Criteria for Active Surveillance Should be Re-evaluated

More and more men who believe they have low-risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate-specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing. Nearly 400 men are now enrolled in the UCLA Active Surveillance program, the largest in Southern California.

Story Continues Below Advertisement

Inspiring a Better Healthcare System- We are the new Change Healthcare

Last spring the majority of McKesson Technology Solutions and Change Healthcare came together, forming a new health IT company with one focus - inspiring a better healthcare system. Click above to learn more.



However, according to a new UCLA study, selection of men for active surveillance should be based not on the widely used conventional biopsy, but with a new, image-guided targeted prostate biopsy. The new biopsy method, pioneered by a multi-disciplinary team on the Westwood campus, is now a routine part of the UCLA active surveillance program.

UCLA researchers found that conventional "blind" biopsy failed to reveal the true extent of presumed low-risk prostate cancers, and that when targeted biopsy was used, more than a third of these men had more aggressive cancers than they thought. Their aggressive cancers were not detected by conventional blind biopsy using ultrasound alone, and the men were referred to UCLA's active surveillance program thinking they were at no immediate risk.

The study appears in the May 19, 2014 issue of the peer-reviewed Journal of Urology.

The targeted biopsy method, under study at UCLA since 2009, is performed by combining magnetic resonance imaging (MRI) with real-time ultrasound, a method of fusion biopsy, in a device known as the Artemis. Previous work from UCLA demonstrated the value of the new procedure in finding cancers in men with rising PSA who had negative conventional biopsies. This study is the first to show the value of using it early in the selection process for men interested in active surveillance.

"These findings are important as active surveillance is a growing trend in this country," said study senior author Dr. Leonard Marks, a professor of urology and director of the UCLA Active Surveillance Program. "It's an excellent option for many men thought to have slow-growing cancers. But we show here that some men thought to be candidates for active surveillance based on conventional biopsies really are not good candidates."

Marks and his team identified 113 men enrolled in the UCLA active surveillance program who met the criteria for having low-risk cancers based on conventional biopsies. Study volunteers underwent an MRI to visualize the prostate and any lesions. That information was then fed into the Artemis device, which fused the MRI pictures with real-time, three-dimensional ultrasound, allowing the urologist to visualize and target lesions during the biopsy.
  Pages: 1 - 2 - 3 >>

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED